Camlin Fine Q3 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 2- Expecting revenue growth of about 25% per year over the next few years (Page 14).
- FY '24 projected to see growth in revenue around 30% to 35% compared to FY '23 (Page 4, 11).
- Volume growth expected despite price corrections and softer chemical prices (Page 13).
- Vanillin plant ramp-up: gradual scaling with commercial realization starting Q1 FY '24; full market penetration over two years (Page 10-11, 15).
- Targeting at least 50% global market share in MEHQ in the next 2 years, with other HQ downstream products also scaling up (Page 12-13).
- Continued growth in blend business at about 30% per year (Page 5).
- Opportunities in specialty natural products and Omega 3 fatty acids expansion planned in next 3-4 years (Page 5).
- Capacity constraints likely to be addressed in FY '24 with discussions for next plant building underway (Page 14).
See what Camlin Fine management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No major capital expenditure is planned for FY '24; the company intends to fund maintenance capex (~INR 20-30 crores) through internal accruals.
- For working capital, an initial requirement of INR 20-30 crores is expected in the first half of FY '24, which will taper down by year-end.
- The company holds a USD 15 million FCCB (Foreign Currency Convertible Bond) option with IFC, likely to be converted at INR 105 crores, which would reduce debt by around INR 115-120 crores.
- No specific mention of new fundraising through fresh debt or equity was made during the call.
- Overall, operational cash flows are expected to improve, supporting debt reduction without the need for significant external borrowing or equity issuance in FY '24.
See what Camlin Fine management said on order book — free account, 30 seconds.
Capex plans
Yes- No major capex planned for FY '24; focus on utilizing internal accruals for maintenance capex (~INR 20-30 crores per annum).
- Working capital requirement may increase by INR 20-30 crores in the first 6 months but expected to taper off by year-end FY '24.
- Discussions in FY '24 about potentially building a new plant to meet demand beyond current capacity (~800 tons/year).
- Expansion priorities in next 2-3 years include growing diphenol downstream products, Aroma business (vanillin, heliotropin), blend business (natural products), and scaling up Omega-3 fatty acid business.
- Vanillin plant commissioned and ramping up; expected to reach near 100% capacity by end of FY '23 but market demand will dictate actual production.
- Growth driven more by capacity utilization and market demand than new large-capex initiatives currently.
Track Camlin Fine — get its next earnings analysis in your feed
Margin guidance
Category 1- The company expects revenue growth of about 25-35% annually for FY 2024 and FY 2025.
- EBITDA margins are projected to expand, driven by scaling up vanillin production and improved yields/processes.
- Vanillin plant ramp-up to 100% production by end of FY 2023, contributing margin accretive revenues starting FY 2024.
- Growth drivers also include increased focus on HQ downstream products like MEHQ, HQEE, para-benzoquinone, and naphthol IRG from FY 2024 onwards.
- Internal cost mitigation programs aim to reduce fixed operating costs by 20%, aiding margin improvement.
- No major capex planned immediately; expansion to be funded via internal accruals.
- Lockheed Martin order post FY 2024 could contribute significantly (over 10-15% of business) depending on market success.
- Despite market price corrections, volume growth and new products expected to sustain profit growth.
Order book
- The company has new orders lining up from Q2 FY '24 onwards, indicating an expected increase in order inflow.
- For Lockheed Martin, the first commercial order is on track for delivery by Q2 FY '24, with further orders under discussion contingent upon product market success.
- The capacities, especially for Lockheed Martin order, are limited right now (around 800 tons/year), expected to fill up by FY '25, prompting discussions for potential new plant construction during FY '24.
- Vanillin is in the sampling phase, with supply expected to start before the end of FY '23 and real production ramping up from Q1 FY '24.
- MEHQ and other downstream products like HQEE, para-benzoquinone, and naphthol IRG are areas of focus for growth, with increasing production planned within available and identified capacities.
- The management expects substantial traction in these product lines in FY '24 and FY '25.
How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Camlin Fine rank in Chemicals & Petrochemicals?
Compare Camlin Fine against every Chemicals & Petrochemicals company (Q3 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…